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Abstract
Many imaging modalities and scanning techniques, such as contrast enhanced CT, MRI and FDG-PET, are available
for assessment of recurrent colorectal carcinoma. In addition, integrated PET/CT is becoming increasingly available.
Intuitively, a synergistic combination of scanning characteristics sounds promising. However, the exact clinical value
has not yet been fully established. The role of PET/CT image fusion must be weighed carefully against other available
modalities. In this review we evaluate the potential of combined PET/CT in recurrent colorectal carcinoma. When
available, PET/CT currently appears the diagnostic tool of choice. In the near future, combined PET/MRI may further
enhance the diagnostic algorithm.
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Introduction
Early detection of recurrent colorectal carcinoma has
become more important in the past decade, as the
treatment options for localized disease have improved
significantly. However, aggressive locoregional interven-
tions (e.g. partial liver resections, radiofrequency ablation
(RFA) of liver metastases, resections of pulmonary
metastases) are as of yet considered futile in the
presence of metastases elsewhere [1]. Therefore, detection
of tumour sites throughout the body is needed with high
sensitivity and specificity. For patient management with
regard to invasive therapy, accurate information about the
local extent of the tumour is also necessary.
Tumour visualization is traditionally performed using
anatomical imaging techniques such as computed tomog-
raphy (CT), ultrasound (US), and magnetic resonance
imaging (MRI). Functional imaging may be of additional
value. Visualization of metabolism with [18F]fluoro-
deoxyglucose positron emission tomography (FDG-PET)
is a valuable tool for detection of primary and recurrent
colorectal cancer [2–4]. Tumour sites may be detected
throughout the body with high contrast resolution.
However, exact localization and demarcation of lesions
with PET is hindered by its relatively low spatial
resolution, and lack of anatomical reference.
The added value of simultaneous contemporaneous
FDG-PET and CT has been demonstrated [5]. As a next
step, the theoretical benefit of the joint capabilities of CT
(anatomical reference) and FDG-PET (accurate tumour
detection) have led to the practice of fusion of the images
obtained by PET/CT. Although promising [6–8], the
technique is relatively new and has limited availability.
Furthermore, PET/CT image fusion may suffer from
artefacts, and the exact clinical value has not yet been
fully established. Therefore, the role of PET/CT image
fusion must be weighed carefully against other more
widely available modalities.
Integration of PET and CT
When considering the combination of PET and CT,
different methods of fusion are available. The most
prevailing approach today is ‘visual fusion’, where
two scans are held side-by-side for comparison and
correlation. Discrepancies between PET and CT may be
resolved with this established technique. When further
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uncertainties persist, integration of the images can prove
to be of additional value. But before attempting to
integrate PET and CT images, some specific issues must
be considered [9].
Scanning characteristics
Tissues appear differently on PET and on CT images. CT
demonstrates anatomy with high spatial resolution, but
with low contrast resolution for soft tissues. On the other
hand, PET visualizes pathological sites with high contrast
resolution, but spatial resolution is limited to 4–7 mm,
and surrounding normal anatomical structures are hardly
visualized. Due to these characteristics, discrepancies
may exist between CT and PET images. Benign lesions
may appear unequivocal on CT but may be negative on
FDG-PET (e.g. cysts, haemangioma, scar tissue), while
intensely FDG-positive lesions may be imperceptible on
CT (e.g. local recurrence, liver metastasis). These char-
acteristics complicate visual recognition and correlation.
Furthermore, positional differences may exist between
PET and CT because of repositioning and/or accidental
voluntary motion. Organs may be displaced or changed in
size (e.g. bowel motion, gastric emptying, bladder filling
between PET and CT scanning). Also administration of
furosemide may contribute to such discrepancies. The
main problem is respiratory mismatch. PET is acquired
during free breathing due to the duration of the scanning
procedure (20–60 min), resulting in slightly blurred
images in the upper abdomen. For correlation purposes,
CT acquisition must be adapted to match these images by
scanning during either free breathing or timed unforced
expiration [9]. Failure to do this correctly will result in
serious localization errors, as the diaphragm (including
lower lung fields and upper abdominal organs such as the
liver) will be relatively displaced.
Software fusion of PET and CT
When separate CT and PET images are available these
may be integrated using specialized software. In such
procedures certain preconditions need to be met. Identical
positioning is a prerequisite. The issue of artefacts due
to breathing motions needs to be addressed by breathing
instructions. The time gap between scans must be limited,
in order to avoid discrepancies due to disease progression
(or regression) during the interval. Specific software
and operator experience are needed. On the whole, the
procedure is lengthy, logistically complex, and it has a
serious risk of registration errors. Some authors do report
adequate results using software fusion, even in the region
of the liver [10], but others strongly disagree [11]. It must at
least be accepted that the bladder region—and possibly
the whole abdomen—has a limited accuracy in image
registration.
Integrated PET/CT scanning
A so-called hybrid scanner consists of separate CT
and PET scanners placed in line, which acquire scans
consecutively without repositioning of the patient. Fusion
of images obtained by these two modalities is often
referred to as ‘hardware fusion’, although this term ought
to be reserved for situations where multiple images
are acquired by a single detector system at the same
time. ‘Hardware’ PET/CT fusion as currently available
reduces (but not fully eliminates) many of the above-
mentioned positioning problems, but the need for an
adequate breathing protocol remains. Other problems
such as bladder filling and bowel motion are reduced to
acceptable levels. When compensating for all sources of
errors, a fusion error below 10mm is generally achievable
in the abdomen [12]. In specific cases this accuracy may
not be reached, for example when a patient is not able to
comply with breathing instructions. This source of error
is important when considering the liver, as the result may
be misplacement of liver lesions in the lung or vice versa,
albeit in a low percentage of scans [13].
When using a hybrid PET/CT scanner, the CT images
can be used for attenuation correction of the PET images.
Although convenient, as the total scanning time can be
reduced by ±35%, any artefact in the CT images may
cause secondary artefacts in the PET images. Examples
of such artefacts are false-positive hotspots related to
attenuating metal such as prosthesis or clips [14], and
hotspots related to intravenous/oral contrast [15]. Further
discrepancies between the PET images and the CT
images may result from bowel movement [16], or when the
patient accidentally moved between the two scans.
Balancing the benefits
Integration of PET and CT can provide synergistic
benefit regardless of the technique applied. Hybrid
PET/CT is more expensive than software fusion, but it
delivers a fast, logistically easy and more reliable image
correlation. A definitive advantage of hybrid PET/CT is
that visual fusion and software fusion may be impossible
or inadequate when demanded ad hoc [11]. In the case
of unexpected findings, integrated PET/CT scanning will
provide adequate images, while software image fusion is
likely to result in suboptimal results.
Interpretation
While fused PET/CT images do appear straightforward,
the above-mentioned characteristics indicate that the
images may not be easy to interpret. The true benefit of
integrated PET/CT not only depends on integration of
images, but also on the integration of expert opinions.
Therefore, it is strongly advised that joint reading
sessions take place with the radiologist and nuclear
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medicine physician with the appropriate clinical input
from clinical oncologists and/or surgeons.
(a) (b)
(c) (d)
Figure 1 Image fusion of contrast-enhanced CT and
FDG-PET. The images show axial and coronal slices
of CT (a, c) and PET (b, d) through the abdomen.
On the CT images, the pelvic recurrence is difficult to
appreciate due to extensive tissuemasses.Within these
masses, the PET image clearly shows a pathological
lesion consistent with local recurrence of malignancy
behind the bladder (white arrow). Image fusion with
CT provided sufficient anatomical reference to guide
a surgical approach.
PET/CT in detection of recurrent
colorectal carcinoma
In the follow-up of colorectal carcinoma, or in suspected
recurrence (e.g. detectable CEA level, residual or newly
formed tissues), the clinically relevant questions to be
answered include: where are the potentially malignant
tissues localized, is a specific lesion malignant or not,
and what is the local extent of a specific lesion? An
important role of imaging is to guide the rational use
of additional invasive diagnostic procedures (e.g. liver
biopsy, colonoscopy, etc.). A second role is demarcation
of lesions to guide locoregional therapy. The role of
PET/CT in relation to other imaging modalities depends
on the indications for the procedure.
Local recurrence
CT is not very accurate for early detection of local
recurrence of colorectal carcinoma, due to the distorted
local anatomy after operation. Selzner et al. demonstrated
a sensitivity of only 53% for CT, and a much better
sensitivity for FDG-PET of 93% [7]. Such excellent
sensitivity in detection of local recurrence also applies
in the evaluation after external beam therapy [17]. The
lack of anatomical reference hampers exact localization
and evaluation of the extent of local pathology on PET
alone. Since these data are essential when considering
therapeutic intervention such as re-excision or irradiation,
PET/CT may be of great value. An example of local
recurrence detection and localization is provided in
Fig. 1. Therefore, for the detection and evaluation of
local recurrence, it is advised to perform PET/CT when
available rather than PET alone.
(a) (b)
(c) (d)
Figure 2 Image fusion of contrast-enhanced CT and
FDG-PET. The images show transverse slices (a, b)
and coronal slices (c, d) through the abdomen of a
patient who previously underwent primary resection
of a sigmoid carcinoma. The PET image clearly
showed a pathological lesion (white arrow), but the
cause remained unclear as no clear lymph node
was found, and the dilated ureter suggested another
explanation (black arrow). Image fusion with CT
could demonstrate correlation with a lymph node that
was overlooked before.
Lymph node metastases
Abdominal lymph node metastases from colorectal
carcinoma tend to be small. Many involved lymph nodes
are below 1 cm in diameter, thus explaining the poor
sensitivity of CT. Some of these small metastases can
be detected by FDG-PET, albeit with a poor sensitivity
of 29%, but with a high specificity of 88% [18]. Problems
arise when a hotspot on PET may correlate with several
anatomical structures including activity excreted in the
urinary tract, blood vessels and bowel polyps, or be
the result of physiological bowel uptake. In these cases,
PET/CT can adequately identify a hotspot, and settle
the diagnosis. Fig. 2 illustrates PET/CT localization of
a pathological lymph node.
S146 Multidisciplinary symposium: colorectal cancer
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Figure 3 Image fusion of contrast-enhanced CT and FDG-PET. The images show transverse slices of the
abdomen through the liver, from CT (a), PET (b) and PET/CT (c). PET shows a clear metastasis in the
ventral border of the liver that is hardly visible on CT, indicating the high sensitivity of FDG-PET, but also
illustrating the need for correlation with anatomical imaging. Furthermore, the image illustrates that FDG-
PET is unaffected by the extensive residual changes and surgical clips posterior in the right liver lobe, after
partial liver resection.
Liver metastases
Ruers et al. demonstrated that FDG-PET as a stand-
alone modality improves diagnostic work-up in patients
with liver metastasis when added to conventional
diagnostic imaging. Furthermore, it has an impact on and
improves therapeutic management [4]. Integrated PET/CT
can provide further value especially in the postoperatively
distorted liver with scar tissue and artificial materials,
where sensitivity and specificity are relatively low for
both CT and MRI [19,20]. After local ablative therapy,
PET may detect recurrence of liver metastasis earlier than
CT [3,21], but correlation with CT is needed for more exact
localization [8]. Conversely, CT may be false-positive at
the rim of the lesions because of hyperperfusion after
RFA, while FDG-PET remains reliable [22]. MRI using
enhancement with manganese containing contrast may
further improve detection of liver metastases and provide
additional information on the nature of liver lesions [23].
Fig. 3 demonstrates that FDG-PET is not affected by
scar tissue and artificial materials. For the detection of
liver metastasis after hepatectomy a sensitivity of 100%
and specificity of 89% was demonstrated for PET/CT,
while the specificity of contrast enhanced CT dropped
to 50% for this specific patient category [7]. An example
of recurrent metastasis in the liver resection area, not
recognized on CT and MRI but detected by FDG-PET
and localized by image fusion, is shown in Fig. 4. For the
evaluation of liver metastases, PET/CT appears to be the
technique of choice.
Extrahepatic metastases
Whole body imaging as a standard procedure is a major
benefit of FDG-PET, thus providing information on
extrahepatic metastases, which has a direct impact on
patient management. Lai et al. demonstrated that 29%
of patients with liver metastases appeared inoperable
because FDG-PET detected extrahepatic metastases [2].
(a) (b)
(c) (d)
Figure 4 Software image fusion of CT, MRI and
FDG-PET. The images show transverse slices through
the liver of a patient who underwent prior RFA
treatment (upper arrow) and liver resection for liver
metastasis of colon carcinoma. Both CT (a) and MRI
(c) are difficult to interpret in the region of the
surgical clips. The PET image (b) clearly shows a
recurrent liver metastasis (lower arrow), which could
be localized only after image fusion withMRI (d). This
permitted guided locoregional therapy.
In recurrent colorectal carcinoma, most extrahepatic
distant metastases will be pulmonary. Detection of
these metastases is of particular importance as surgical
intervention may still be possible, by combining liver
surgery with resection of a limited number of pulmonary
lesions [24,25]. Both CT and FDG-PET have demonstrated
high sensitivity for pulmonary lesions, but PET may
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be particularly helpful in discriminating benign from
malignant lesions [26]. FDG-PET has also demonstrated
added value in detection of other extrahepatic distant
metastases such as bone metastases [27]. In unexpected
extrahepatic lesions detected by PET, exact localization
may be very hard without correlative anatomical imaging
as provided by PET/CT. This also applies to the detection
of unexpected second primaries, which may occur in
approximately 1% of cases [28].
Lesion characterization
Regardless of the type of lesion as seen on imaging, dif-
ferentiation of benign from malignant disease is always
a challenge. Both CT and FDG-PET can contribute to
the final diagnosis, but a combination of both modalities
delivers the strongest diagnostic tool [29,30]. Given this
asset, we consider PET/CT the best option when atypical
lesions need to be characterized at the highest possible
level of accuracy, especially in cases where a definitive
diagnosis through pathology cannot be obtained.
Future developments
The true clinical value of FDG-PET—and the added
value of the application of PET/CT scanners—should
ideally be clarified by prospective clinical trials. But
a true comparison between separately acquired PET
and CT images, visual fusion, software fusion, and
integrated PET/CT images can hardly be achieved, as
this implies the acquisition of multiple scans with a
high cumulative radiation burden to the patient. As a
result of the rather limited scientific evidence, the current
choices for implementation of FDG-PET in diagnostic
strategies appear rather random, and large variations exist
among institutes. This also applies to the application of
hybrid PET/CT scanning for various specific questions.
Nevertheless, scientific evidence about the diagnostic
values of PET and PET/CT are increasing rapidly, and
eagerly awaited.
New PET tracers
Besides visualization of glucose metabolism with FDG,
PET scanning may be applied for in vivo non-invasive
evaluation of other tissue characteristics using tracers
other than FDG. For example, DNA synthesis activity
may be quantitatively assessed using [18F]fluoro-deoxy-
L-thymidine (FLT), as a reflection of cell proliferation
and tumour growth [31]. The exact clinical applicability
of FLT, as well as several other tracers currently under
investigation, is at present even less clear than the utility
of FDG-PET. It is to be expected that many new tracers
will accumulate selectively in pathological lesions, and
will show poor or no normal tissue activity. These images
may therefore be uninterpretable without integration of
PET and CT.
Integration of PET and MRI
The combination of PET and CT is not the only
possibility, nor is it a perfect solution. On theoretical
grounds it is preferable to combine PET with (functional)
MRI, for better soft tissue evaluation with a relatively
low radiation burden. An excellent example of the
application of PET/MRI fusion is accurate delineation of
malignant lesions in the liver, to allow optimally guided
locoregional therapeutic intervention. The PET/MRI
fusion procedure is already possible when using software
fusion; an example is shown in Fig. 4. It is expected
that integrated PET/MRI scanners will become clinically
available in the next 5 years.
Conclusions
The combination of PET and CT is currently proving
itself as a valuable tool in the diagnostic strategy for
detection of recurrent colorectal carcinoma, especially
in the field of staging before surgical re-interventions.
This has an impact on diagnosis and choice of therapy.
The application of separate PET and CT is not to
be considered ‘second class’, when visually correlated
adequately. Although unbiased supporting literature is
currently limited, hardware integrated PET/CT using
a hybrid scanner does seem to be able to improve
diagnostic accuracy over correlated stand-alone PET and
CT in several specific cases. As software image fusion is
prone to error, this technique should be used with caution
and should be reserved for specific applications.
The largest benefit from integration of PET and CT
images depends on the integration of knowledge. This
implies joint consensus reading by a multidisciplinary
team. This will be of even greater importance when new
PET tracers and new MRI applications enter the clinical
field.
With the increasing availability of integrated PET/CT
scanners, it is to be expected that clinical use and
experience will rapidly expand. However, a critical
review of indications and added value of these techniques
are a prerequisite for rational application and maximum
diagnostic yield.
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